SCHEMBL1027117

SCHEMBL1027117

CC(C)(C)N(C(=O)O)c1cccc(COCc2cccc([N+](=O)[O-])c2)c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.47
MAOA P21397 1/20 0.47
RAB9A P51151 1/20 0.47
CYP2D6 P10635 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
CYP1A2 P05177 1/20 0.46
ALDH1A1 P00352 5/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
LMNA P02545 3/20 0.44
PKM P14618 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HTT P42858 1/20 0.44
MAPT P10636 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
RECQL P46063 1/20 0.42
FFAR1 O14842 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1027116 1.00 MAOB (0.47) MAOBMAOARAB9ACYP2D6CYP2C9
SCHEMBL1026158 0.86 CYP1A2 (0.46) RAB9ACYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL1026157 0.86 CYP1A2 (0.46) RAB9ACYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL2453170 0.85 TP53 (0.49) RAB9AALDH1A1MEN1KMT2ALMNA
SCHEMBL2453168 0.85 TP53 (0.49) RAB9AALDH1A1MEN1KMT2ALMNA
SCHEMBL1025248 0.84 CYP1A2 (0.50) MAOBMAOARAB9ACYP2D6CYP2C9
SCHEMBL1025247 0.84 CYP1A2 (0.50) MAOBMAOARAB9ACYP2D6CYP2C9
SCHEMBL1023439 0.82 CYP2D6 (0.43) RAB9ACYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL1023436 0.82 CYP2D6 (0.43) RAB9ACYP2D6CYP2C9CYP2C19CYP1A2
Trifluoroacetic Acid SCHEMBL1028315 0.81 OPRM1 (0.49) CYP2D6CYP2C9CYP2C19CYP1A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2274288-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS Incyte Corporation (US) 2011-01-19 EP disclosed